Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis.

Autor: Heseltine J; The Clatterbridge Cancer Centre, Clatterbridge Road, Bebington, Liverpool, CH63 4JY, UK. J.heseltine@nhs.net.; The University of Liverpool, Liverpool, UK. J.heseltine@nhs.net., Allison J; The Christie, Manchester, UK., Wong S; The Royal Marsden, London, UK., Prasad K; East Lancashire Teaching Hospitals, Lancashire, UK., Oong ZC; East Lancashire Teaching Hospitals, Lancashire, UK., Wong H; The Clatterbridge Cancer Centre, Clatterbridge Road, Bebington, Liverpool, CH63 4JY, UK., Law A; The Clatterbridge Cancer Centre, Clatterbridge Road, Bebington, Liverpool, CH63 4JY, UK., Charnley N; East Lancashire Teaching Hospitals, Lancashire, UK., Parikh O; East Lancashire Teaching Hospitals, Lancashire, UK., Waddell T; The Christie, Manchester, UK., Chow S; The Clatterbridge Cancer Centre, Clatterbridge Road, Bebington, Liverpool, CH63 4JY, UK.
Jazyk: angličtina
Zdroj: Targeted oncology [Target Oncol] 2023 Jul; Vol. 18 (4), pp. 593-599. Date of Electronic Publication: 2023 Jun 07.
DOI: 10.1007/s11523-023-00972-8
Abstrakt: Background: Tivozanib is a licensed as first-line treatment for metastatic renal cell carcinoma (mRCC).
Objective: To evaluate the outcomes from tivozanib in a real-world mRCC population.
Patients and Methods: Patients with mRCC commencing first-line tivozanib between March 2017 and May 2019 were identified across four specialist cancer centres in the UK. Data relating to response, overall survival (OS), progression-free survival (PFS) and adverse events (AEs) were collected retrospectively with censoring on 31 December 2020.
Results: A total of 113 patients were identified: median age was 69 years; 78% had ECOG PS 0-1; 82% had clear cell histology; 66% had previous nephrectomy; International Metastatic RCC Database Consortium (IMDC) score was 22% favourable (F), 52% intermediate (I) and 26% poor (P). Twenty-six per cent were switched from another tyrosine kinase inhibitor (TKI) to tivozanib due to toxicity. Median follow-up was 26.6 months with 18% remaining on treatment at data censoring. Median PFS was 8.75 months. Median PFS by IMDC risk group was: F = 23.0 months; I = 10.0 months; P = 3.0 months, p value < 0.0001. Median OS was 25.0 months (F = not reached (NR) with 72% alive at data cut-off; I = 26.0 months; P = 7.0 months, p value < 0.0001). Seventy-seven per cent had an AE of any grade, and 13% had a grade ≥ 3 AE. Eighteen per cent of patients discontinued treatment due to toxicity. No patients who discontinued a prior TKI due to AEs stopped tivozanib due to AEs.
Conclusions: These data suggest comparable activity of tivozanib with the pivotal trial data and other TKIs in a real-world population. Its tolerability positions tivozanib as an attractive first-line option for those unsuitable for combination therapies or unable to tolerate other TKIs.
(© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Databáze: MEDLINE
Externí odkaz: